In September 2021, Amazon launched Amazon Care, a virtual care service for its employees. The combined company will provide a comprehensive suite of virtual care services, including telemedicine, chronic condition management, and behavioral health services. In October 2020, Teladoc Health and Livongo, two of the largest virtual care providers, announced a merger. The COVID-19 pandemic has also accelerated the adoption of virtual care, as healthcare providers have been forced to adopt remote healthcare solutions to reduce the risk of infection. The rising prevalence of chronic diseases, the shortage of healthcare professionals, and the need for cost-effective healthcare solutions are also driving the demand for virtual care. The demand for virtual care is primarily driven by the increasing adoption of digital technologies in the healthcare industry. The global virtual care market has experienced significant growth in recent years due to the increasing demand for remote healthcare services and the growing adoption of telemedicine. Virtual care refers to the delivery of healthcare services through digital communication technologies, such as video conferencing, messaging, and other telecommunication technologies. That same data showed cervical cancer was the fourth most common cancer in women in 2020, with approximately 604,000 cases and 342,000 deaths from the disease worldwide.New York, Ma(GLOBE NEWSWIRE) - The Virtual Care Market is estimated to be US$ 10,017.3 million in 2023 to US$ 122.33 Billion by 2033, With at a CAGR of 17.4% during the forecast period 2023 to 2033. Persistent genital HPV infection is responsible for almost all cases of cervical pre-cancerous lesions, which can lead to cervical carcinoma, according to WHO data. It is estimated that about 291 million women worldwide are carriers of human papillomavirus (HPV) DNA. Vaccitech confirmed that these latest results will be presented orally at next month’s International Papillomavirus Conference in Washington DC. VTP-200 was well-tolerated with no product-related grade 3 unsolicited events and no product-related SAEs, as per the interim data readout. Immunogenicity results showed high responses, defined as an average greater than 1,000 spot-forming units per million peripheral blood mononuclear cells in an ELISPOT assay, especially to the E1, E2, and E6 antigens, it continued.
#THE PERSISTENCE TWITTER TRIAL#
The ongoing Phase 1b/2 clinical trial of VTP-200, called HPV001, is designed to assess the safety and efficacy of VTP-200 and determine the optimal immunotherapeutic dose regimen in women with HPV-related low grade cervical lesions.ĭata from the first 58 women enrolled who reached their six-month timepoint in the HPV001 placebo-controlled study were reviewed internally, and the trial will continue as planned to the 12-month primary endpoint, said the UK firm.
It co-invented a COVID-19 vaccine with the University of Oxford, which is now approved and exclusively licensed worldwide to AstraZeneca.Īlong with VTP-200, the company’s lead product candidates include VTP-300, an immunotherapy candidate designed as a component of a potential component of a functional cure for chronic hepatitis B viral (HBV) infection VTP-850, a novel T cell investigational therapy for prostate cancer and VTP-1000, a preclinical T cell therapeutic product candidate for immune tolerance in celiac disease. Vaccitech, a spin out company from the University of Oxford’s Jenner Institute, is developing products to treat and prevent infectious disease and cancer.
0 kommentar(er)
